Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:PODD

Insulet Q2 2026 Earnings Report

Insulet logo
$157.46 -4.09 (-2.53%)
Closing price 07/8/2026 04:00 PM Eastern
Extended Trading
$158.61 +1.15 (+0.73%)
As of 06:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Insulet EPS Results

Actual EPS
N/A
Consensus EPS
$1.45
Beat/Miss
N/A
One Year Ago EPS
N/A

Insulet Revenue Results

Actual Revenue
N/A
Expected Revenue
$787.82 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Insulet Announcement Details

Quarter
Q2 2026
Date
8/5/2026
Time
Before Market Opens
Conference Call Date
Wednesday, August 5, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Insulet Earnings Headlines

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD
July 8 at 10:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/09/3324521/673/en/ROSEN-GLOBAL-INVESTOR-COUNSEL-Encourages-Insulet-Corporation-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-PODD.html
Robbins LLP Urges PODD Investors Who Lost Money Investing in Insulet Corporation to Contact the Firm for Information About Leading the Class Action
July 8 at 6:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324496/32719/en/robbins-llp-urges-podd-investors-who-lost-money-investing-in-insulet-corporation-to-contact-the-firm-for-information-about-leading-the-class-action.html
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
July 9 at 1:00 AM  |  Profits Run (Ad)
Levi & Korsinsky Reminds Insulet Corporation Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 31, 2026 - PODD
July 8 at 5:31 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/levi--korsinsky-reminds-insulet-corporation-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-31-2026---podd-302821158.html
Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut?
July 8 at 3:05 PM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-insulet-corporation-podd-stock-still-a-diabetes-device-growth-opportunity-after-analyst-target-cut-1797681/
Deadline Alert: Insulet Corporation (PODD) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
July 8 at 3:05 PM  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2026/07/08/10411810.htm
See More Insulet Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Insulet? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insulet and other key companies, straight to your email.

About Insulet

Insulet (NASDAQ:PODD) is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery. Insulet has advanced its platform to include systems with automated insulin delivery capabilities that integrate with continuous glucose monitoring (CGM) technologies to provide hybrid closed-loop functionality. In addition to hardware, the company offers related software, connectivity features and customer support services to enable remote monitoring and data sharing with caregivers and clinicians.

Insulet operates in multiple international markets, with sales and distribution across North America, Europe, Asia-Pacific and other regions through direct channels and local partners. The company has positioned itself around innovation in tubeless pump technology, ongoing product development and regulatory engagement to expand indications and integrations. Insulet’s business model combines recurring revenues from disposable Pods and supplies with investments in research and development, manufacturing scale-up and commercial expansion to broaden access to its insulin-delivery solutions globally.

View Insulet Profile
Earnings Tools